New Study Reports Two Thirds Of Renal Recipients Switched To myfortic(R) Experience An Improvement In Gastrointestinal Symptom Burden
A large-scale open label non-comparative study published this week in Transplantation demonstrates that, following conversion from mycophenolate mofetil therapy (MMF) to myfortic(R) (mycophenolic acid) delayed-release tablets, gastrointestinal (GI) complaints in kidney recipients are improved and sustained over the three month trial1. Up to 45 percent of recipients experience GI side effects with MMF2. [click link for full article]
More: continued here
Filed under: GastroIntestinal / Gastroentorology on December 20th, 2007